Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    ABX464

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abivax Reports Phase 3 ABTECT Trial Results For Obefazimod
    Abivax Reports Phase 3 ABTECT Trial Results For Obefazimod

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304711/0/en/abivax-announces-landmark-phase-3-abtect-maintenance-trial-results-evaluating-obefazimod-in-moderately-to-severely-active-ulcerative-colitis.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Abivax Reports Q1 2026 Results and 3-Year Obefazimod OLE Data
    Abivax Reports Q1 2026 Results and 3-Year Obefazimod OLE Data

    22 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/22/3300344/0/en/abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a-2b-open-label-extension-trial-of-obefazimod-following-dose-de-esc.html

    GLOBENEWSWIRE
    22 May 2026
    Share Share
    Abivax To Present Data On Obefazimod At Digestive Disease Week
    Abivax To Present Data On Obefazimod At Digestive Disease Week

    22 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/22/3279387/0/en/abivax-to-present-data-on-obefazimod-at-digestive-disease-week.html

    GLOBENEWSWIRE
    22 Apr 2026
    Share Share
    Abivax Reveals 2025 Financials And Business Updates
    Abivax Reveals 2025 Financials And Business Updates

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260837/0/en/Abivax-Announces-Full-Year-2025-Financial-Results-and-Provides-Business-Updates.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Abivax Unveils Obefazimod's Anti-Fibrotic Activity In IBD
    Abivax Unveils Obefazimod's Anti-Fibrotic Activity In IBD

    21 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/21/3242210/0/en/Abivax-Presents-First-Evidence-of-Anti-Fibrotic-Activity-for-Obefazimod-Alongside-New-Clinical-Efficacy-and-Safety-Analyses-in-Inflammatory-Bowel-Disease-at-ECCO-2026.html

    GLOBENEWSWIRE
    21 Feb 2026
    Share Share
    Abivax Provides 2026 Corporate Outlook
    Abivax Provides 2026 Corporate Outlook

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214893/0/en/Abivax-Provides-2026-Corporate-Outlook.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.